CD274 and cancer: Resistance to anti-PD-1 therapy has been described in treated human patients via the selection of cancer cell variants with somatic mutations that inactivate JAK1, or JAK2 or that abrogate β2-microblobulin expression.81,82 These cell variants have become intrinsically resistant to interferon-induced apoptosis and do not up-regulate PD-L1.